These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Maximum standardized uptake value from quantitative bone single-photon emission computed tomography/computed tomography in differentiating metastatic and degenerative joint disease of the spine in prostate cancer patients. Mohd Rohani MF, Mat Nawi N, Shamim SE, Wan Sohaimi WF, Wan Zainon WMN, Musarudin M, Said MA, Hashim H. Ann Nucl Med; 2020 Jan; 34(1):39-48. PubMed ID: 31612417 [Abstract] [Full Text] [Related]
4. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases. Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod Lalonde M. BMC Musculoskelet Disord; 2019 Dec 26; 20(1):619. PubMed ID: 31878904 [Abstract] [Full Text] [Related]
6. Correlation between the maximum standard uptake value and mean Hounsfield unit on single-photon emission computed tomography-computed tomography to discriminate benign and metastatic lesions among patients with breast cancer. Saminathan ST, Ahmed WAW, Nawi NM, Tagiling N, Aziz I, Udin Y, Rohani MFM, Zainon WMNW, Razab MKAA. Asian Spine J; 2024 Jun 26; 18(3):398-406. PubMed ID: 38917860 [Abstract] [Full Text] [Related]
9. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M. Eur J Hybrid Imaging; 2017 Jun 26; 1(1):2. PubMed ID: 29782587 [Abstract] [Full Text] [Related]
12. Comparison of standardized uptake values between 99mTc-HDP SPECT/CT and 18F-NaF PET/CT in bone metastases of breast and prostate cancer. Arvola S, Jambor I, Kuisma A, Kemppainen J, Kajander S, Seppänen M, Noponen T. EJNMMI Res; 2019 Jan 24; 9(1):6. PubMed ID: 30680469 [Abstract] [Full Text] [Related]
14. A retrospective study of SPECT/CT scans using SUV measurement of the normal pelvis with Tc-99m methylene diphosphonate. Wang R, Duan X, Shen C, Han D, Ma J, Wu H, Xu X, Qin T, Fan Q, Zhang Z, Shi W, Guo Y. J Xray Sci Technol; 2018 Jan 24; 26(6):895-908. PubMed ID: 30103368 [Abstract] [Full Text] [Related]
17. Quantification evaluation of 99mTc-MDP concentration in the lumbar spine with SPECT/CT: compare with bone mineral density. Huang K, Feng Y, Liu D, Liang W, Li L. Ann Nucl Med; 2020 Feb 24; 34(2):136-143. PubMed ID: 31768820 [Abstract] [Full Text] [Related]
19. Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study. Oya T, Ichikawa Y, Nakamura S, Tomita Y, Sasaki T, Inoue T, Sakuma H. Ann Nucl Med; 2023 Jun 24; 37(6):360-370. PubMed ID: 36947324 [Abstract] [Full Text] [Related]
20. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP. Pietrzak A, Czepczynski R, Wierzchoslawska E, Cholewinski W. Hell J Nucl Med; 2017 Jun 24; 20(3):237-240. PubMed ID: 29177262 [Abstract] [Full Text] [Related] Page: [Next] [New Search]